Emmaus Life Sciences, Inc. (EMMA)
D
Pipeline Grade
Financial Position (from SEC Filings)
$1.1M
Cash & Equivalents
$0.3M
Quarterly Burn Rate
9 mo
Est. Cash Runway
$1M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-06-30 | Phase3 Readout | — |
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06252649 | Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Particip... | PHASE3 | Recruiting | 450 |
| NCT05920356 | A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-L... | PHASE3 | Recruiting | 750 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.